Overview

Efficacy of Luspatercept in ESA-naive LR-MDS Patients With or Without Ring Sideroblasts Who do Not Require Transfusions

Status:
Not yet recruiting
Trial end date:
2027-07-31
Target enrollment:
Participant gender:
Summary
Anemia in patients with very low, low or intermediate risk myelodysplastic syndromes (MDS), that are non-transfusion dependent
Phase:
Phase 2
Details
Lead Sponsor:
University of Leipzig
Collaborator:
Celgene Corporation
Treatments:
Luspatercept